COMMUNIQUÉS West-GlobeNewswire

Nightstar Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional American Depositary Shares
02/10/2017
LEXINGTON, Mass. and LONDON, Oct. 02, 2017 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc ("Nightstar" or the "Company") (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited [...]
NuCana plc Announces Closing of Initial Public Offering of ADSs and Exercise of Underwriters' Option to Purchase Additional ADSs
02/10/2017
EDINBURGH, United Kingdom, Oct. 02, 2017 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq:NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying its [...]
Ossur Hf : Transactions in relation to share buyback program
02/10/2017
Announcement from Össur hf. No. 70/2017 Reykjavík, 2 October 2017 On 15 August 2017, Össur hf. initiated a share buy-back program, see Company announcement no. 59/2017. The purpose of the share buyback program is to [...]
GLOBAL BIOENERGIES : PUBLICATION DES RESULTATS SEMESTRIELS AU 30/06/2017
02/10/2017
GLOBAL BIOENERGIES : PUBLICATION DES RESULTATS SEMESTRIELS AU 30/06/2017 Perte nette du Groupe de 7,8 M€ sur le premier semestre 2017 Trésorerie nette de 8,4 M€ au 30 juin 2017, juste avant l'opération d'augmentation de [...]
GLOBAL BIOENERGIES: PUBLICATION OF THE HALF-YEAR RESULTS TO 30/06/2017
02/10/2017
GLOBAL BIOENERGIES: PUBLICATION OF THE HALF-YEAR RESULTS TO 30/06/2017 Net loss for the Group of €7.8 million in the first half of 2017 €8.4 million net cash at 30 June 2017, immediately prior to the €10.2 million [...]
Status regarding Novo Nordisk's holding of its own shares (30 September 2017)
02/10/2017
Bagsværd, Denmark, 2 October 2017 - In continuation of the company's announcements dated 3 May 2017 and 9 August 2017 concerning planned share repurchase programmes, and pursuant to Section 204.25 of the New York Stock [...]
Shire plc : Total voting rights
02/10/2017
Total Voting Rights October 2, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company"), in accordance with 5.6.1R of the Financial Conduct Authority's (the "FCA") Disclosure Guidance and Transparency Rules, notifies [...]
Novo Nordisk A/S - Share repurchase programme
02/10/2017
Bagsværd, Denmark, 2 October 2017 - On 2 February 2017, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 [...]
Sanofi Appoints Stefan Oelrich Executive Vice President Diabetes & Cardiovascular
02/10/2017
Sanofi Appoints Stefan Oelrich Executive Vice President Diabetes & Cardiovascular and Member of the Executive Committee Paris, France - October 2, 2017 - Sanofi today announced the appointment of Stefan Oelrich as [...]
Sanofi nomme Stefan Oelrich au poste de Vice-Président Exécutif, Diabète et Cardiovasculaire
02/10/2017
Sanofi nomme Stefan Oelrich au poste de Vice-Président Exécutif, Diabète et Cardiovasculaire, et membre du Comité Exécutif Paris, France - Le 2 octobre 2017 - Sanofi a nommé Stefan Oelrich au poste de Vice-Président [...]
Summit Therapeutics to Host R&D Day 11 October 2017
02/10/2017
Summit Therapeutics plc ("Summit", or the "Company") SUMMIT THERAPEUTICS TO HOST R&D DAY 11 OCTOBER 2017 Oxford, UK, 2 October 2017 - Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and [...]
uniQure Announces Company Presentations at Upcoming October Conferences
02/10/2017
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Oct. 02, 2017 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE) a leading gene therapy company advancing transformative therapies for patients with severe medical needs, [...]
RedHill Biopharma Accelerates RHB-104 Phase III Study in Crohn's Disease with Top-Line Results Expected Mid-2018
02/10/2017
RedHill has curtailed the target sample size in the ongoing first Phase III study with RHB-104 for Crohn's disease (MAP US) from 410 to approximately 325 subjects, of which 322 have been enrolled to date, while [...]
Vistin Pharma ASA : Sale of Opioids and CMO business completed
02/10/2017
Oslo, Norway, 2 October 2017 Norwegian pharmaceutical company Vistin Pharma ASA ("Vistin Pharma") announced today that the Company has successfully completed the sale of its opioids and tablet manufacturing business ( [...]
GENFIT annonce sa participation au congrès de l'AASLD 2017
02/10/2017
GENFIT annonce sa participation au congrès de l'AASLD 2017 Nouveaux résultats indiquant un potentiel anti-fibrotique substantiel d'une combinaison propriétaire de deux médicaments issus de la pharmacopée Nouvelles [...]
GENFIT announces its participation at the 2017 AASLD Meeting
02/10/2017
GENFIT announces its participation at the 2017 AASLD Meeting New results indicating a substantial anti-fibrotic potential of a proprietary combination of two drugs from the pharmacopoeia Novel approaches for the [...]
Solon Eiendom ASA : Salg i Q3 2017
02/10/2017
Oslo, oktober 2, 2017 - Solon Eiendom solgte 23 boliger med en samlet verdi på 185 millioner kroner i tredje kvartal i år sammenlignet med 38 boliger med en samlet verdi på 230 millioner kroner i tredje kvartal i fjor. [...]
Solon Eiendom ASA : Sales in Q3 2017
02/10/2017
Oslo, October 2, 2017 - Solon Eiendom sold 23 homes with a total sales value of NOK 185 million during the third quarter of 2017 compared to 38 homes with a total sales value of NOK 230 million in the third quarter of [...]
Verona Pharma plc : Total voting rights
02/10/2017
October 2, 2017, LONDON - Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) ("Verona Pharma"), in conformity with DTR 5.6 of the FCA's Disclosure and Transparency Rules, notifies the market that as at 30 September 2017, the [...]

Pages